Vesalio’s enVast Meets NATURE Trial Endpoint in STEMI
Dallas, Texas, August 29, 2026 Vesalio announced positive results from the NATURE randomized controlled trial, evaluating the company’s enVastâ„¢...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Dallas, Texas, August 29, 2026 Vesalio announced positive results from the NATURE randomized controlled trial, evaluating the company’s enVastâ„¢...
